For instance, in one patient, a second episode of acute lymphoblastic leukemia (ALL) from 13 years after the original occurrence was determined to be a very late relapse rather than a new leukemia on the basis of a shared JAK2 driver variant and was therefore treated with relapse therapy. This evidence concerns the gene JAK2 and leukemia.